To examine the safety profile of FL090 in the brain, we intragastrically administered FL090 (5 mg/kg, for 18 days, a dose we intended to treat the PD mice) to C57 BL/6 mice and observed significantly reduced LRRK2 kinase activity, evidenced by reduced phosphorylation at pS935 (Figure 1J). This evidence concerns the gene LRRK2 and Parkinson disease.